These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21246289)

  • 1. Using structural equation modeling to detect response shift in performance and health-related quality of life scores of multiple sclerosis patients.
    King-Kallimanis BL; Oort FJ; Nolte S; Schwartz CE; Sprangers MA
    Qual Life Res; 2011 Dec; 20(10):1527-40. PubMed ID: 21246289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study.
    Morales-Gonzáles JM; Benito-León J; Rivera-Navarro J; Mitchell AJ;
    Mult Scler; 2004 Feb; 10(1):47-54. PubMed ID: 14760952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using structural equation modeling to detect response shifts and true change in discrete variables: an application to the items of the SF-36.
    Verdam MG; Oort FJ; Sprangers MA
    Qual Life Res; 2016 Jun; 25(6):1361-83. PubMed ID: 26694962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?
    Kragt JJ; Nielsen JM; van der Linden FA; Polman CH; Uitdehaag BM
    Mult Scler; 2011 Feb; 17(2):234-40. PubMed ID: 20978037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mediating effect of coping on the association between fatigue and quality of life in patients with multiple sclerosis.
    Mikula P; Nagyova I; Krokavcova M; Vitkova M; Rosenberger J; Szilasiova J; Gdovinova Z; Groothoff JW; van Dijk JP
    Psychol Health Med; 2015; 20(6):653-61. PubMed ID: 25879302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
    Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
    Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
    Hadjimichael O; Vollmer T; Oleen-Burkey M;
    Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS).
    Doward LC; McKenna SP; Meads DM; Twiss J; Eckert BJ
    Mult Scler; 2009 Sep; 15(9):1092-102. PubMed ID: 19556315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The initial course of daily functioning in multiple sclerosis: a three-year follow-up study.
    de Groot V; Beckerman H; Lankhorst GJ; Polman CH; Bouter LM
    Mult Scler; 2005 Dec; 11(6):713-8. PubMed ID: 16320733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X; Comi G; O'Connor P; Gold S; de Vera A; Eckert B; Kappos L
    Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis.
    Pilutti LA; Dlugonski D; Sandroff BM; Klaren R; Motl RW
    Mult Scler; 2014 Apr; 20(5):594-601. PubMed ID: 24009162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.
    Riazi A; Hobart JC; Lamping DL; Fitzpatrick R; Thompson AJ
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):701-4. PubMed ID: 12438473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.
    Yalachkov Y; Soydaş D; Bergmann J; Frisch S; Behrens M; Foerch C; Gehrig J
    Mult Scler Relat Disord; 2019 May; 30():33-37. PubMed ID: 30735970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis?
    Rasova K; Brandejsky P; Havrdova E; Zalisova M; Rexova P
    Mult Scler; 2005 Apr; 11(2):213-21. PubMed ID: 15794397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depressive Symptoms and Suicidal Ideation in Progressive Multiple Sclerosis Compared With Relapsing-Remitting Multiple Sclerosis: Results From a Cross-sectional Survey.
    Knowles LM; Esselman EC; Turner AP; Phillips KM; Herring TE; Alschuler KN; Ehde DM
    Arch Phys Med Rehabil; 2021 Apr; 102(4):694-701. PubMed ID: 33080210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process.
    Zhang Y; Taylor BV; Simpson S; Blizzard L; van der Mei I
    Eur J Neurol; 2019 Jan; 26(1):155-161. PubMed ID: 30133059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales.
    Sonder JM; Bosma LV; van der Linden FA; Knol DL; Polman CH; Uitdehaag BM
    Mult Scler; 2012 Feb; 18(2):196-201. PubMed ID: 21908479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olfactory dysfunction in multiple sclerosis: association with secondary progression.
    Silva AM; Santos E; Moreira I; Bettencourt A; Coutinho E; Gonçalves A; Pinto C; Montalban X; Cavaco S
    Mult Scler; 2012 May; 18(5):616-21. PubMed ID: 22020420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
    Hawton A; Green C; Telford CJ; Wright DE; Zajicek JP
    Mult Scler; 2012 Jun; 18(6):853-61. PubMed ID: 22108867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study.
    Pappalardo A; Chisari CG; Montanari E; Pesci I; Borriello G; Pozzilli C; D'Amico E; Patti F
    Mult Scler Relat Disord; 2017 Oct; 17():154-171. PubMed ID: 29055451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.